Clinical Trials Browser

Phase 2 × INDUSTRY × ofatumumab × Clear all

Oncology Patients Receiving Chemotherapy

NCT01294579 2018-08-09

Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)

Phase 2 Completed

49 enrolled 13 charts

Lymphoid

Lymphoma, Non-Hodgkin, Recurrence

NCT00811733 2017-05-30

A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia

Phase 2 Completed

37 enrolled 25 charts

Lymphoid

Waldenstrom Macroglobulinemia

NCT01077622 2017-05-30

A Phase I/II, a Single Arm, Open-label Study of Ofatumumab (GSK1841157) in Patients With Previously Treated Chronic Lymphocytic Leukemia

Phase 2 Completed

10 enrolled 35 charts

LymphoidOther hematologic neoplasm

Leukemia, B-Cell

NCT01520922 2017-01-19

Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)

Phase 2 Completed

99 enrolled 27 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphoid, Neoplasms, Recurrence, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01563055 2015-08-10

A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia

Phase 2 Completed

10 enrolled 52 charts

LymphoidOther hematologic neoplasm

Leukemia, B-Cell

NCT00622388 2015-07-24

Ofatumumab in Patients With Relapsed/Progressive Diffused Large B-Cell Lymphoma (DLBCL) Ineligible for or Relapse/Progression After Transplant

Phase 2 Completed

81 enrolled 18 charts

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT00494780 2014-07-11

MUNIN

Phase 2 Completed

59 enrolled 21 charts

Lymphoid

Lymphoma, Follicular

NCT00349349 2014-06-04

HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab

Phase 2 Completed

223 enrolled 31 charts

LymphoidOther hematologic neoplasm

Leukemia, B-Cell

NCT00410163 2014-02-10

BIFROST

Phase 2 Completed

61 enrolled 22 charts

LymphoidOther hematologic neoplasm

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00394836 2014-01-29

HuMax-CD20 i(Ofatumumab) n Follicular Lymphoma (FL) Patients Refractory to Rituximab

Phase 2 Completed

116 enrolled 22 charts

Lymphoid

Lymphoma, Follicular

NCT00823719 2013-03-12

Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Phase 2 Completed

61 enrolled 25 charts

Lymphoid

Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT01108341 2012-08-28

Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL)

Phase 2 Completed

50 enrolled 10 charts

Lymphoid

Lymphoma, Non-Hodgkin

Clinical Trials

versus

Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)

A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia

A Phase I/II, a Single Arm, Open-label Study of Ofatumumab (GSK1841157) in Patients With Previously Treated Chronic Lymphocytic Leukemia

Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)

A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia

Ofatumumab in Patients With Relapsed/Progressive Diffused Large B-Cell Lymphoma (DLBCL) Ineligible for or Relapse/Progression After Transplant

MUNIN

HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab

BIFROST

HuMax-CD20 i(Ofatumumab) n Follicular Lymphoma (FL) Patients Refractory to Rituximab

Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL)